NCT03552263View on ClinicalTrials.gov

Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

PHASE2CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

June 7, 2018

Primary Completion Date

October 20, 2019

Study Completion Date

November 10, 2019

Conditions
Acute Mountain Sickness (AMS)
Interventions
DRUG

T89 capsule

T89 capsules (75mg), orally, twice daily.

DRUG

Placebo capsule

Placebo capsules (0mg), orally, twice daily.

Trial Locations (1)

94143

Hypoxia Research Lab, UCSF Parnassus Campus, S-256, San Francisco

All Listed Sponsors
lead

Tasly Pharmaceuticals, Inc.

INDUSTRY

NCT03552263 - Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS) | Biotech Hunter | Biotech Hunter